Avalyn Pharma(AVLN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

AVLN Avalyn Pharma

Trading 10-21 13:08:51 EDT

25.29

+0.66

+2.68%

High25.29	Low22.99	Vol50.23K
Open24.74	D1 Closing24.63	Amplitude9.34%
Mkt Cap1.12B	Tradable Cap421.50M	Total Shares44.33M
T/O1.25M	T/O Rate0.30%	Tradable Shares16.67M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"AVLN","market":"US","secType":"STK","nameCN":"Avalyn Pharma","latestPrice":25.29,"timestamp":1792602521122,"preClose":24.63,"halted":0,"volume":50234,"delay":0,"changeRate":0.026796589524969557,"floatShares":16666700,"shares":44333095,"eps":-2.33,"marketStatus":"Trading","change":0.66,"latestTime":"10-21 13:08:51 EDT","open":24.74,"high":25.29,"low":22.99,"amount":1247053.02192,"amplitude":0.093382,"askPrice":25.42,"askSize":133,"bidPrice":25.18,"bidSize":10,"shortable":3,"etf":0,"ttmEps":-2.33,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1792612800000},"marketStatusCode":2,"adr":0,"listingDate":1777521600000,"exchange":"NASDAQ","adjPreClose":24.63,"postHourTrading":{"tag":"盘后","latestPrice":24.63,"preClose":24.63,"latestTime":"19:30 EDT","volume":5488,"amount":135169.44,"timestamp":1792539002652,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.386896,"impliedVol":0.6903,"impliedVolPercentile":0.7907},"requestUrl":"/m/hq/s/AVLN","defaultTab":"news","newsList":[{"id":"1124625844","title":"Morgan Stanley Initiates Eight Biotech Names, Rating Seven Overweight","url":"https://stock-news.laohu8.com/highlight/detail?id=1124625844","media":"Analyst Calls","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1124625844?lang=en_us&edition=fundamental","pubTime":"2026-10-20 10:11","pubTimestamp":1792462284,"startTime":"0","endTime":"0","summary":"","market":"hk","thumbnail":"https://static.tigerbbs.com/96e20408c3934de428b82e38a778cc26","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/96e20408c3934de428b82e38a778cc26"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Morgan Stanley Initiates Eight Biotech Names, Rating Seven Overweight","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RGNX","BLTE","PTCT","CMPS","TRVI","AVLN"],"isVideo":true,"video":{"duration":320,"video_url":"https://news-video-sg.skytigris.cn/videos/remotion/3928/render_3928_1792461663591.mp4","video_thumbnail":"https://news-video-sg.skytigris.cn/videos/covers/3928.webp","audio_url":"https://news-video-sg.skytigris.cn/videos/remotion/3928/tts/voiceover_2510d0822d39909bff1e8933.mp3","isAI":true},"gpt_icon":0},{"id":"2675936329","title":"Syndax Pharmaceuticals Stock Plunges. a Failed Trial Deals Blow to Growth Plans.","url":"https://stock-news.laohu8.com/highlight/detail?id=2675936329","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675936329?lang=en_us&edition=fundamental","pubTime":"2026-10-13 23:24","pubTimestamp":1791905040,"startTime":"0","endTime":"0","summary":"Syndax Pharmaceuticals stock plunged on Tuesday after the drugmaker reported disappointing trial results for a lung disease treatment, dealing a setback to its efforts to expand the market for one of ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BFXG1179.USD","LU2596442595.SGD","LU0321505868.SGD","LU1585245621.USD","LU1718418525.SGD","LU0237698245.USD","BK4588","LU0267386448.USD","LU1236620750.USD","BMY","BK4581","LU0114720955.EUR","LU1670710588.SGD","LU0321505439.SGD","LU1430594728.SGD","LU1868836591.USD","LU2242652126.USD","LU1868837136.USD","AVLN","SNDX","LU0096364046.USD","LU0306806265.USD","LU1670711123.USD","LU0868494617.USD","LU1571399168.USD","FTXH","LU0061475181.USD","IE00BJT1NW94.SGD","LU2360032135.SGD","LU2125154778.USD","LU1670710661.SGD","LU2242646821.SGD","LU0225284248.USD","LU0432979614.USD","SNY","LU0456855351.SGD","LU1868836914.USD","LU1868836757.USD","LU2125154935.USD","IHE","IE00BSNM7G36.USD","BK4559","LU1323610961.USD","BK4534","LU1291159041.SGD","LU1983299246.USD","LU1989771016.USD","LU1074936037.SGD","IE00BJJMRZ35.SGD","LU1261432733.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672489715","title":"Avalyn Pharma initiated with an Outperform at Raymond James","url":"https://stock-news.laohu8.com/highlight/detail?id=2672489715","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672489715?lang=en_us&edition=fundamental","pubTime":"2026-10-02 17:45","pubTimestamp":1790934320,"startTime":"0","endTime":"0","summary":"Raymond James analyst Tiago Fauth initiated coverage of Avalyn Pharma (AVLN) with an Outperform rating and $60 price target Avalyn is developing in...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/avalyn-pharma-initiated-with-an-outperform-at-raymond-james-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/avalyn-pharma-initiated-with-an-outperform-at-raymond-james-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AVLN","RJF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669162378","title":"Avalyn Pharma Reports Phase 1 Data for Inhaled Nintedanib AP02 Showing Higher Lung Exposure, Lower Systemic Levels","url":"https://stock-news.laohu8.com/highlight/detail?id=2669162378","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669162378?lang=en_us&edition=fundamental","pubTime":"2026-09-22 00:11","pubTimestamp":1790007085,"startTime":"0","endTime":"0","summary":"Avalyn Pharma reports Phase 1 data for inhaled nintedanib AP02 showing higher lung exposure, lower systemic levelsAvalyn Pharma flagged aRespiratory Researchpublication detailing Phase 1 trials of inh","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260921:nNDLbxKbJx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","SG9999014039.USD","IE00BQXX3F31.USD","SG9999014005.SGD","SG9999014021.USD","NDAQ","IE00B64PRP62.GBP","BK4588","IE00BN0W2V16.EUR","LU2210149790.SGD","IE00B3QW5Z07.USD","IE00BQXX3C00.GBP","AVLN","BK4585","IE00BN0W2W23.USD","IE00BN0W2T93.GBP","LU2210150020.SGD","IE00BGHQF748.EUR","LU0314104364.USD","IE00BKPKM429.USD","IE00BQXX3D17.EUR","BCDF","LU2095319765.USD","BK4112","SG9999014013.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669661341","title":"Avalyn Pharma announces published results from Phase 1 trials of AP02","url":"https://stock-news.laohu8.com/highlight/detail?id=2669661341","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669661341?lang=en_us&edition=fundamental","pubTime":"2026-09-21 21:10","pubTimestamp":1789996248,"startTime":"0","endTime":"0","summary":"Avalyn Pharma (AVLN) announced that Respiratory Research has published detailed results from two Phase 1 clinical trials of AP02 in healthy volunte...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/avalyn-pharma-announces-published-results-from-phase-1-trials-of-ap02-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/avalyn-pharma-announces-published-results-from-phase-1-trials-of-ap02-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BMED","BK4007","IDNA","MEDX","AVLN","HYLG","BBC","GDOC","NVIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668054994","title":"Avalyn Pharma Director Robert J. Meyer Files Initial Beneficial Ownership Statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2668054994","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668054994?lang=en_us&edition=fundamental","pubTime":"2026-09-18 04:06","pubTimestamp":1789675617,"startTime":"0","endTime":"0","summary":"Avalyn Pharma Director Robert J. Meyer files initial beneficial ownership statementAvalyn Pharma director Robert J. Meyer filed an initial Form 3 beneficial ownership statement dated Sept. 15, 2026.Di","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260917:nNDL9Q9vwJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVLN","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668933628","title":"Avalyn Appoints Robert J. Meyer, Md, to Its Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2668933628","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668933628?lang=en_us&edition=fundamental","pubTime":"2026-09-17 04:01","pubTimestamp":1789588860,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260916:nTUA8THHQK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AVLN","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668933933","title":"Press Release: Avalyn Appoints Robert J. Meyer, MD, to Its Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2668933933","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668933933?lang=en_us&edition=fundamental","pubTime":"2026-09-17 04:01","pubTimestamp":1789588860,"startTime":"0","endTime":"0","summary":"BOSTON, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc. (Nasdaq: AVLN) (\"Avalyn\" or the \"Company\"), a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treat","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABU","BK4585","AVLN","BK4007","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662620570","title":"Avalyn Pharma Advances Inhaled Pirfenidone AP01 in Phase 2b MIST Trial for Progressive Pulmonary Fibrosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2662620570","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662620570?lang=en_us&edition=fundamental","pubTime":"2026-08-25 04:01","pubTimestamp":1787601686,"startTime":"0","endTime":"0","summary":"Avalyn Pharma advances inhaled pirfenidone AP01 in Phase 2b MIST trial for progressive pulmonary fibrosisAvalyn Pharma slated two ERS Congress 2026 posters on Sept. 7 in Barcelona, spotlighting patien","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nNDL2B5BVh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","LU2210150020.SGD","AVLN","SG9999014039.USD","IE00BGHQF748.EUR","LU0314104364.USD","BCDF","BK4588","IE00BN0W2T93.GBP","IE00B64PRP62.GBP","LU2095319765.USD","SG9999014021.USD","SG9999014005.SGD","SG9999014013.SGD","IE00BQXX3D17.EUR","IE00BQXX3C00.GBP","BK4585","NDAQ","IE00BQXX3F31.USD","BK4112","IE00B3QW5Z07.USD","BK4007","IE00BN0W2W23.USD","LU2210149790.SGD","IE00BN0W2V16.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661298158","title":"One new option listing and two option delistings on August 21st","url":"https://stock-news.laohu8.com/highlight/detail?id=2661298158","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661298158?lang=en_us&edition=fundamental","pubTime":"2026-08-21 20:35","pubTimestamp":1787315738,"startTime":"0","endTime":"0","summary":"New option listings for August 21st include Avalyn Pharma Inc (AVLN). Option delistings effective August 21st include Liberty Broadband (LBRDK) and...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/one-new-option-listing-and-two-option-delistings-on-august-21st-thefly-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/one-new-option-listing-and-two-option-delistings-on-august-21st-thefly-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4534","BK4561","BK4007","LBRDK","BK4100","AVLN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660424488","title":"Avalyn Pharma price target raised to $57 from $53 at Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2660424488","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660424488?lang=en_us&edition=fundamental","pubTime":"2026-08-17 16:02","pubTimestamp":1786953775,"startTime":"0","endTime":"0","summary":"Morgan Stanley raised the firm’s price target on Avalyn Pharma (AVLN) to $57 from $53 and keeps an Overweight rating on the shares. Published first...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/avalyn-pharma-price-target-raised-to-57-from-53-at-morgan-stanley-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/avalyn-pharma-price-target-raised-to-57-from-53-at-morgan-stanley-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AVLN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659165881","title":"Jefferies Sticks to Its Buy Rating for Avalyn Pharma Inc (AVLN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2659165881","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659165881?lang=en_us&edition=fundamental","pubTime":"2026-08-13 22:45","pubTimestamp":1786632342,"startTime":"0","endTime":"0","summary":"In a report released today, Roger Song from Jefferies maintained a Buy rating on Avalyn Pharma Inc, with a price target of $52.00. Song covers the ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/jefferies-sticks-to-its-buy-rating-for-avalyn-pharma-inc-avln-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/jefferies-sticks-to-its-buy-rating-for-avalyn-pharma-inc-avln-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AVLN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659687091","title":"Avalyn Pharma is Maintained at Overweight by Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2659687091","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659687091?lang=en_us&edition=fundamental","pubTime":"2026-08-13 22:26","pubTimestamp":1786631160,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/AVLN/analyst-ratings","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVLN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658972423","title":"Avalyn Pharma Q2 EPS $(0.65) Misses $(0.53) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2658972423","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658972423?lang=en_us&edition=fundamental","pubTime":"2026-08-12 20:13","pubTimestamp":1786536803,"startTime":"0","endTime":"0","summary":"Avalyn Pharma (NASDAQ:AVLN) reported quarterly losses of $(0.65) per share which missed the analyst consensus estimate of $(0.53) by 22.64 percent.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/08/61138966/avalyn-pharma-q2-eps-0-65-misses-0-53-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVLN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658972464","title":"Earnings Flash (AVLN) Avalyn Pharma Posts Q2 Net Loss $28.9M, vs. FactSet Est of $28.6M Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2658972464","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658972464?lang=en_us&edition=fundamental","pubTime":"2026-08-12 20:12","pubTimestamp":1786536741,"startTime":"0","endTime":"0","summary":"Earnings Flash (AVLN) Avalyn Pharma Posts Q2 Net Loss $28.9M, vs. FactSet Est of $28.6M Loss","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AVLN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658115972","title":"Avalyn Pharma Q2 FY26 Net Loss Widens to $28.94 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2658115972","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658115972?lang=en_us&edition=fundamental","pubTime":"2026-08-12 20:09","pubTimestamp":1786536565,"startTime":"0","endTime":"0","summary":"Avalyn Pharma Q2 FY26 net loss widens to $28.94 millionAvalyn Pharma posted a GAAP net loss of USD 28.9 million in Q2 2026, widening from USD 20.2 million a year earlier.R&D expense climbed to USD 24.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nNDL1mnfcT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014013.SGD","BK4585","IE00BN0W2T93.GBP","LU2095319765.USD","LU2210149790.SGD","BK4007","BCDF","IE00BKPKM429.USD","AVLN","IE00B3QW5Z07.USD","BK4588","NDAQ","LU0314104364.USD","LU2210150020.SGD","BK4112","IE00B64PRP62.GBP","IE00BN0W2V16.EUR","IE00BN0W2W23.USD","SG9999014039.USD","IE00BGHQF748.EUR","SG9999014005.SGD","SG9999014021.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658972189","title":"Press Release: Avalyn Reports Second Quarter 2026 Financial Results and Recent Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2658972189","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658972189?lang=en_us&edition=fundamental","pubTime":"2026-08-12 20:00","pubTimestamp":1786536000,"startTime":"0","endTime":"0","summary":"double-blind, placebo-controlled global trial evaluating two doses of. AP01 dosed twice daily in patients with progressive pulmonary fibrosis. . This 52-week trial is designed to assess safety and efficacy of. AP01, with a primary endpoint of change in lung function measured by. forced vital capacity . The study overenrolled beyond its target. enrollment of 375, with a total of 398 patients randomized into three. treatment cohorts. Topline data are anticipated in the second half of. -- In September 2026, the Company plans to present two abstracts at the ERS. Congress in Barcelona, Spain. The first poster will highlight data. modeling effective AP01 distribution throughout the target tissue in both. healthy and idiopathic pulmonary fibrosis  lungs. The second poster. will describe the integration of patient perspectives into clinical trial. design. Detailed poster session information will be provided in advance","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GDOC","MEDX","IDNA","BK4007","NVIB","HYLG","FVC","AVLN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644450557","title":"Avalyn Pharma completes target enrollment in MIST trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2644450557","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644450557?lang=en_us&edition=fundamental","pubTime":"2026-06-17 20:15","pubTimestamp":1781698555,"startTime":"0","endTime":"0","summary":"Avalyn Pharma (AVLN) announced that it has completed target enrollment of 375 patients in the Phase 2b MIST clinical trial of AP01 in patients with...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/avalyn-pharma-completes-target-enrollment-in-mist-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/avalyn-pharma-completes-target-enrollment-in-mist-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MIST","AVLN","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644745938","title":"Avalyn Pharma completes enrollment in Phase 2b MIST trial of inhaled pirfenidone for progressive pulmonary fibrosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2644745938","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644745938?lang=en_us&edition=fundamental","pubTime":"2026-06-17 20:02","pubTimestamp":1781697779,"startTime":"0","endTime":"0","summary":"Avalyn Pharma completed target enrollment of 375 patients in the Phase 2b MIST trial of AP01 for progressive pulmonary fibrosis.Results have not been presented; topline data are expected in the second half of 2027.The study is designed to assess whether inhaled pirfenidone can better preserve lung function versus placebo over 52 weeks.Management cited earlier-stage data suggesting tolerability that could support longer time on therapy, a potential differentiator in the disease.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260617:nNDL6CpYww:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","IE00BGHQF748.EUR","IE00BKPKM429.USD","SG9999014021.USD","NDAQ","SG9999014039.USD","LU0314104364.USD","IE00B3QW5Z07.USD","LU2210149790.SGD","IE00BN0W2V16.EUR","LU2210150020.SGD","SG9999014013.SGD","LU2095319765.USD","IE00BN0W2T93.GBP","IE00BN0W2W23.USD","BK4007","AVLN","BK4585","BK4588","SG9999014005.SGD","IE00B64PRP62.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644745656","title":"Avalyn Pharma - Topline Data From Mist Trial Expected in Second Half of 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2644745656","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644745656?lang=en_us&edition=fundamental","pubTime":"2026-06-17 20:00","pubTimestamp":1781697602,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260617:nTUA4X2JZZ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","AVLN"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.avalynpharma.com","stockEarnings":[{"period":"1week","weight":0.0375},{"period":"1month","weight":-0.2186},{"period":"3month","weight":-0.1424},{"period":"6month","weight":0.3683},{"period":"ytd","weight":0.3683}],"compareEarnings":[{"period":"1week","weight":-0.0115},{"period":"1month","weight":0.0097},{"period":"3month","weight":0.029},{"period":"6month","weight":0.0855},{"period":"1year","weight":0.1456},{"period":"ytd","weight":0.1278}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Avalyn Pharma Inc. was incorporated in the state of Delaware on May 27, 2011. The company is a clinical-stage biopharmaceutical company developing inhaled therapies for the treatment of rare respiratory diseases, including progressive pulmonary fibrosis, idiopathic pulmonary fibrosis, and other interstitial lung diseases.","exchange":"NASDAQ","name":"Avalyn Pharma","nameEN":"Avalyn Pharma"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Avalyn Pharma(AVLN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Avalyn Pharma(AVLN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Avalyn Pharma,AVLN,Avalyn Pharma股票,Avalyn Pharma股票老虎,Avalyn Pharma股票老虎国际,Avalyn Pharma行情,Avalyn Pharma股票行情,Avalyn Pharma股价,Avalyn Pharma股市,Avalyn Pharma股票价格,Avalyn Pharma股票交易,Avalyn Pharma股票购买,Avalyn Pharma股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Avalyn Pharma(AVLN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Avalyn Pharma(AVLN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}